Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Zhejiang University. Science. B|January 4, 2020
Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myelomaHe Huang, Heng-Wei Wu, Yong-Xian Hu
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 29, 2011
Relapsing hematologic malignancies after haploidentical hematopoietic stem cell transplantationYong-Xian Hu, Qu Cui, Bin Liang, et al.
Onkologie|April 15, 2010
Donor-derived solid malignancies after hematopoietic stem cell transplantationYong-xian Hu, Qu Cui, Bin Liang, et al.
Current Medical Science|July 4, 2021
Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological MalignanciesKe-Jia Hu, Elaine Tan Su Yin, Yong-Xian Hu, et al.
Journal of Zhejiang University. Science. B|April 12, 2021
Weathering the storm: COVID-19 infection in patients with hematological malignanciesLin-Qin Wang, Elaine Tan Su Yin, Guo-Qing Wei, et al.
Zhongguo Ying Yong Sheng Li Xue Za Zhi = Zhongguo Yingyong Shenglixue Zazhi = Chinese Journal of Applied Physiology|February 19, 2011
[Anti-cD20scFv/CD80/CD28/zeta specific T lymphocytes eradicate primary chronic lymphocytic leukemia cells in vitro]Hong-Lan Qian, Kang Yu, Zhi-Jian Shen, et al.
Zhongguo Ying Yong Sheng Li Xue Za Zhi = Zhongguo Yingyong Shenglixue Zazhi = Chinese Journal of Applied Physiology|December 15, 2010
[Construction of recombinant retroviruses expressing anti-CD20 scFv/CD80 /CD28/zeta gene and expression in Jurkat cell line]Yong-Xian Hu, Kang Yu, Ying-Xia Tan, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|July 27, 2007
[Construction of anti-cD20scFv/CD80/CD28/zeta recombinant gene modified T cell and research on its targeting cytotoxicity]Yong-Xian Hu, Kang Yu, Ying-Xia Tan, et al.
Leukemia & Lymphoma|June 8, 2013
Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathwaysKang-Ni Wu, Yan-Min Zhao, Ying He, et al.
Frontiers in Immunology|September 16, 2022
Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapyTing-Ting Yang, Ye Meng, De-Lin Kong, et al.
Pageof 1